The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Recent collaborations highlight a growing interest in building a multiomics-based understanding of health and disease.

The targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments, studies suggest.

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder ...

Donegal High School held its commencement June 5. The graduates are: Ayomikun Rehoboth Akinrinwoye, Maria Gabriela Aleman ...

England becomes the first country to offer the world’s pioneering 'Trojan horse' blood cancer drug, through NHS, promising ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

THOU DOTH PORTEST — Protests are set to pop up around the Bay State this weekend, capping off a week of tension between the ...